Signal
A pair of phase 3 psoriasis studies of Alumis’ TYK2 inhibitor have hit their primary endpoints, setting the biotech up to file for approval of a potential ch...
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-01-06 16:50 UTCUpdated 2026-01-07 10:47 UTC
rss
fierce_biotech
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral options for psoriasis, among them drugs from Takeda and Johnson & Johnson.
Score total
1.02
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
All evidence
All evidence
A pair of phase 3 psoriasis studies of Alumis’ TYK2 inhibitor have hit their primary endpoints, setting the biotech up to file for approval of a potential challenger to Bristol ...
Fierce Biotech (All) · fiercebiotech.com · 2026-01-07 10:47 UTC
Alumis soars as TYK2 drug hits mark in psoriasis trials
BioPharma Dive (Latest) · biopharmadive.com · 2026-01-06 16:50 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Biotech (All) (1)
- BioPharma Dive (Latest) (1)
Top origin domains (this list)
- fiercebiotech.com (1)
- biopharmadive.com (1)